Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVID-globulin for Moderate COVID-19
NCT04842435Phase 3Unknown
- Sponsor
- MicroGen Biotech
- Start
- Apr 2021
- Primary completion
- Sep 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of CoviGlobulin in coronavirus disease 2019 (COVID-19), sponsored by MicroGen Biotech. Status: unknown.
02
Drugs
CoviGlobulin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04842435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04842435.